SLNP-based CDK4- targeted nanotherapy against glioblastoma
Our results indicated that Sil and SLNP-Sil are promising therapeutic approaches against glioblastoma and merit <i>in vivo</i> experimental verification using orthotropic xenograft mouse models against glioblastoma.
Authors
- Tawaf Ali Shah (ORCID: https://orcid.org/0000-0002-5030-4729)
- Fareeha Khalid Ghori
- Saira Justin (ORCID: https://orcid.org/0009-0009-5274-8401)
- Mohammed Bourhia (ORCID: https://orcid.org/0000-0003-3707-8461)
- Sabahat Habib (ORCID: https://orcid.org/0009-0004-8256-3997)
- Basit Azad
- Uzma Ghani
- Hina Khan (ORCID: https://orcid.org/0000-0003-3886-8377)
- Aneela Javed (ORCID: https://orcid.org/0000-0003-0280-0610)
- Muhammad Usman Qamar (ORCID: https://orcid.org/0000-0002-2636-238X)
- Ishaq Khan (ORCID: https://orcid.org/0000-0001-6110-9403)
- Fouzia Perveen
- Gamal A. Shazly
Institutions
- University of Geneva (CH)
- Shandong University of Technology (CN)
- Government College University, Faisalabad (PK)
- Khyber Medical University (PK)
- King Saud University (SA)
- Université Ibn Zohr (MA)
- National University of Sciences and Technology (PK)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-11-22
- DOI
- https://doi.org/10.3389/fonc.2024.1455816
- Citations
- 2
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.35
Funders
- King Saud University
- National University of Sciences and Technology
- Higher Education Commision, Pakistan
- US-Pakistan Centre for Advanced Studies in Energy, University of Engineering and Technology, Peshawar